Abstract
Background: Trastuzumab(T) plus lapatinib(L) has been demonstrated to significantly improve the outcome of HER2 positive heavily pretreated metastatic breast cancer (MBC) patients. Whether TL combined chemotherapy (TLC) can further improve the efficacy in HER2+ MBC remains to be further studied. The aim of this study was to assess real-world treatment patterns and clinical outcomes of patients treated with TLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
